TABLE 1.

Protection against a challenge M. tuberculosis infection in CD4−/− mice reconstituted with CD4+ T cells and vaccinated with Ag85B DNAa

Mouse treatment parameterLog10 mRLU (SD)b
SpleenLungs
WT (4 wk)CD4−/− (4 wk)CD4−/− (8 wk)WT (4 wk)CD4−/− (4 wk)CD4−/− (8 wk)
Naive (n = 4)3.57 (0.13)4.72 (0.29)4.74 (0.47)4.80 (0.17)5.08 (0.40)5.45 (0.07)
Ag85B DNA (n = 4)3.42 (0.03)4.96 (0.39)5.33 (0.14)4.20 (0.34)*4.75 (0.40)5.25 (0.30)
BCG (n = 4)3.43 (0.09)3.73 (0.26)**ND3.71 (0.13)**3.80 (0.30)**ND
AT (20 × 106 CD4+ T cells) (n = 3)4.37 (0.14)4.49 (0.14)5.24 (0.16)5.40 (0.10)
AT (20 × 106 CD4+ T cells) + control DNA (n = 4)ND4.58 (0.3)ND5.63 (0.22)
AT (5 × 106 CD4+ T cells) + Ag85B DNA (n = 4)4.57 (0.15)ND5.17 (0.33)ND
AT (20 × 106 CD4+ T cells) + Ag85B DNAc4.28 (0.38)*4.1 (0.24)**5.22 (0.29)5.05 (0.50)
  • a Eight weeks after the third dose of pDNA vaccination and 8 weeks after BCG vaccination, mice received a luminescent M. tuberculosis challenge (2 × 105 CFU = 5 log10 mRLU/mouse, intravenously). Four and eight weeks later, viable bacterial counts in spleen and lungs were determined by luminescence.

  • b *, P < 0.05; **, P <0.01 (compared to Ag85B DNA-vaccinated CD4−/− mice for reconstituted CD4−/− mice and compared to naïve mice for the other groups); ND, not done.

  • c n = 5 at 4 weeks; n = 4 at 8 weeks.